MA33533B1 - Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles - Google Patents

Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles

Info

Publication number
MA33533B1
MA33533B1 MA34640A MA34640A MA33533B1 MA 33533 B1 MA33533 B1 MA 33533B1 MA 34640 A MA34640 A MA 34640A MA 34640 A MA34640 A MA 34640A MA 33533 B1 MA33533 B1 MA 33533B1
Authority
MA
Morocco
Prior art keywords
disorders
diseases
treatment
proliferative
cancer
Prior art date
Application number
MA34640A
Other languages
Arabic (ar)
English (en)
Inventor
Vijayalakshmi Ramanan
Irene Sophie Tobias
Dauntel Specht Verwijs
Raymond D Skwierczynski
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33533(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA33533B1 publication Critical patent/MA33533B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques inédites contenant le composé de formule (I) : (formule I), ou un sel pharmaceutiquement acceptable de celui-ci, et pouvant être utilisées pour la production en série d'une forme galénique destinée à la voie orale. L'invention concerne également des procédés de production de ladite forme galénique destinée à la voie orale et l'utilisation de ladite composition pharmaceutique dans le cadre du traitement de patients souffrant de maladies, de troubles ou d'affections impliquant la survie, la prolifération et la migration cellulaires, dont les affections prolifératives inflammatoires chroniques, les affections oculaires prolifératives, les troubles prolifératifs bénins et les cancers ou, encore, dans le cadre du traitement de patients sujets à de tels troubles, maladies ou affections.
MA34640A 2009-07-31 2012-02-16 Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles MA33533B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31
PCT/US2010/002109 WO2011014248A1 (fr) 2009-07-31 2010-07-28 Compositions pharmaceutiques utilisables dans le cadre du traitement du cancer et d'autres maladies ou affections

Publications (1)

Publication Number Publication Date
MA33533B1 true MA33533B1 (fr) 2012-08-01

Family

ID=42697590

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34640A MA33533B1 (fr) 2009-07-31 2012-02-16 Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles

Country Status (30)

Country Link
US (3) US20110039826A1 (fr)
EP (1) EP2459173B1 (fr)
JP (2) JP2013500965A (fr)
KR (1) KR101762285B1 (fr)
CN (2) CN103893186B (fr)
AR (1) AR077436A1 (fr)
AU (1) AU2010276741B2 (fr)
BR (1) BR112012002265B8 (fr)
CA (1) CA2769531C (fr)
CL (1) CL2012000261A1 (fr)
CO (1) CO6612185A2 (fr)
CR (1) CR20120084A (fr)
EA (1) EA025277B1 (fr)
EC (1) ECSP12011703A (fr)
GE (1) GEP201606513B (fr)
IL (1) IL217839A (fr)
IN (1) IN2012DN01237A (fr)
JO (1) JO3434B1 (fr)
MA (1) MA33533B1 (fr)
MX (2) MX2012001196A (fr)
MY (1) MY174084A (fr)
NZ (1) NZ598096A (fr)
PE (1) PE20120788A1 (fr)
SG (2) SG177751A1 (fr)
TN (1) TN2012000046A1 (fr)
TW (1) TWI522357B (fr)
UA (1) UA110463C2 (fr)
UY (1) UY32822A (fr)
WO (1) WO2011014248A1 (fr)
ZA (1) ZA201200944B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005243175B2 (en) * 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
RU2535032C2 (ru) 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
BR112012020557A8 (pt) 2010-02-19 2018-01-02 Millennium Pharm Inc formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2014153509A1 (fr) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
EP3076963A4 (fr) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs de kinase aurora et d'anticorps anti-cd30
WO2017015316A1 (fr) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration d'inhibiteur de kinase aurora et d'agents chimiothérapeutiques
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface
CN121941495A (zh) 2023-10-03 2026-04-28 武田药品工业株式会社 用于治疗小细胞肺癌的阿立塞替和紫杉醇
WO2025245045A1 (fr) 2024-05-21 2025-11-27 The Regents Of The University Of California Méthodes de traitement du cancer du poumon

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
EP0946523A1 (fr) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Derives polycyclique fondus de 2-aminopyrimidine, leur preparation et leur utilisation comme inhibiteurs de proteine tyrosine-kinase
AU784971B2 (en) 1999-08-11 2006-08-10 Biogen Inc. Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
KR20030019327A (ko) * 2000-03-24 2003-03-06 아이박스 리서치 인코포레이티드 탁산-기저 조성물을 안정시키는 금속염의 용도
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
AU2005243175B2 (en) * 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
EA200870117A1 (ru) * 2005-12-23 2008-12-30 Смитклайн Бичам Корпорейшн Азаиндоловые ингибиторы аурора-киназ
JP2009542664A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増大させる置換されたピペリジンの使用の方法
PT2046292E (pt) * 2006-07-21 2010-04-26 Novartis Ag Formulações de éteres benzimidazolil-piridílicos
US7718648B2 (en) * 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
RU2535032C2 (ru) * 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
BR112012020557A8 (pt) * 2010-02-19 2018-01-02 Millennium Pharm Inc formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio

Also Published As

Publication number Publication date
TW201107331A (en) 2011-03-01
CO6612185A2 (es) 2013-02-01
CA2769531A1 (fr) 2011-02-03
ZA201200944B (en) 2015-07-29
EA201270205A1 (ru) 2012-07-30
BR112012002265A2 (pt) 2016-06-14
EP2459173A1 (fr) 2012-06-06
MX2012001196A (es) 2012-03-14
IL217839A0 (en) 2012-03-29
MY174084A (en) 2020-03-09
KR101762285B1 (ko) 2017-07-28
WO2011014248A1 (fr) 2011-02-03
US20160158244A1 (en) 2016-06-09
NZ598096A (en) 2014-05-30
JP2013500965A (ja) 2013-01-10
CN103893186A (zh) 2014-07-02
EA025277B1 (ru) 2016-12-30
JP6014695B2 (ja) 2016-10-25
US9504693B2 (en) 2016-11-29
IN2012DN01237A (fr) 2015-05-15
IL217839A (en) 2017-01-31
BR112012002265B1 (pt) 2021-01-12
CN103893186B (zh) 2019-07-09
UA110463C2 (ru) 2016-01-12
KR20120053008A (ko) 2012-05-24
MX348197B (es) 2017-06-05
UY32822A (es) 2011-01-31
AU2010276741B2 (en) 2016-07-14
SG10201404483VA (en) 2014-10-30
BR112012002265B8 (pt) 2021-05-25
CL2012000261A1 (es) 2012-08-03
TN2012000046A1 (en) 2013-09-19
ECSP12011703A (es) 2012-03-30
CA2769531C (fr) 2017-11-07
AU2010276741A1 (en) 2012-03-01
AR077436A1 (es) 2011-08-24
US20110039826A1 (en) 2011-02-17
JO3434B1 (ar) 2019-10-20
EP2459173B1 (fr) 2018-02-28
TWI522357B (zh) 2016-02-21
CR20120084A (es) 2012-06-01
US9127011B2 (en) 2015-09-08
PE20120788A1 (es) 2012-07-22
CN102548539A (zh) 2012-07-04
SG177751A1 (en) 2012-02-28
GEP201606513B (en) 2016-07-25
US20140073630A1 (en) 2014-03-13
JP2015091877A (ja) 2015-05-14

Similar Documents

Publication Publication Date Title
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA38138A1 (fr) Dérivés inédits de quinolone
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA29791B1 (fr) Composes therapeutiques.
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA32798B1 (fr) Acides naphtylacétiques
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
MA35932B1 (fr) Pyrazolopyrimidinyle inhibiteurs de l'enzyme d'activation de l'ubiquitine
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA31950B1 (fr) Composition pharmaceutique
MA45867B1 (fr) Modulateurs du récepteur des oestrogènes